The present invention relates to Myc dominant negative mutant, referred to as Omomyc, with what medicine and with what prevention and/or treating cancer. The invention further relates to the fusion protein comprising Omomyc and its pharmaceutical composition and their purposes in medicine, especially use the purposes of what treating cancer.本發明涉及Myc顯性負突變體，稱爲Omomyc，其用於醫藥以及用於預防和／或治療癌症。本發明還涉及包含Omomyc的融合蛋白及其藥物組合物以及它們在醫藥中的用途，特別是用於治療癌症的用途。
